NEW YORK, NY / ACCESSWIRE / October 5, 2017 / U.S. markets continue to reach new record highs in the fourth quarter on strong economic data. The Dow Jones Industrial Average gained 0.09 percent to close at a record high of 22,661.64, while the S&P 500 Index hit an intra-day record of 2,540.53 before settling to close at a record 2,537.74, an increase of 0.12 percent. The NASDAQ Composite Index increased 0.04 percent to close at 6,534.63. This was the third consecutive session that all 3 major indexes closed at a new record high. On Wednesday, the Institute for Supply Management reported its index of non-manufacturing activity grew to 59.8 in September from 55.3 in August. The reading was the highest since August 2005.
"Volatility has also been kind of lackluster. Every day we come in and there are new highs," said Anthony Conroy, President at Abel Noser. "That said, there is more room to run higher for stocks. The economy is strong, earnings are good and volatility remains low."
RDI Initiates Coverage on:
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.'s stock edged 0.72% higher Wednesday, to close the day at $39.14. The stock recorded a trading volume of 1,828,318 shares, which was above its three months average volume of 1,396,540 shares. In the last year, ACADIA Pharmaceuticals Inc.'s shares have traded in a range of 20.68 - 40.83. The share price has gained 89.26% from its 52-week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $35.38 is greater than its 200-day moving average of $31.57. Shares of ACADIA Pharmaceuticals have gained approximately 35.71 percent year-to-date.
Access RDI's ACADIA Pharmaceuticals Inc. Research Report at:
On Wednesday, shares of ImmunoGen Inc. recorded a trading volume of 2,053,368 shares, which was below the three months average volume of 3,525,990 shares. The stock ended the day 2.35% higher at 7.83. The share price has gained 418.54% from its 52-week low with a 52-week trading range of 1.51 - 8.84.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $7.01 is greater than its 200-day moving average of $5.51. Shares of ImmunoGen have gained approximately 283.82 percent year-to-date.
Access RDI's ImmunoGen Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.